Project Grant R21NS135481
Award Date
6/21/24
Completion Date
5/31/26
Dollars Obligated
$450K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas MD Anderson Cancer Center to develop and validate a tumor-bearing mouse model of oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN). The goal is to create a preclinical model that replicates key features of CIPN observed in colorectal cancer patients, including...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $181,448 to Virginia Commonwealth University to determine whether the drug dapansutrile, a selective NLRP3 inflammasome inhibitor, can alleviate and prevent chemotherapy-induced peripheral neuropathy (CIPN) in a mouse model. The project aims to test the hypothesis that NLRP3 inflammasome activation contributes to paclitaxel-induced CIPN, and that inhibition of NLRP3 can mitigate these...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of Schwann cell dysfunction and repair signaling in chemotherapy-induced painful peripheral neuropathy (CIPPN). The research will examine the potential of targeting peroxisome proliferator-activated receptor gamma (PPARG) and low-density lipoprotein receptor-related protein 1 (LRP1) signaling in...
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
This Project Grant award of $601,091.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at The Ohio State University to investigate the role of the inflammatory molecule S100A9 in mitigating paclitaxel-induced peripheral neuropathy (PIPN). The key objectives are to: (I) characterize the mechanism by which S100A9 contributes to PIPN, focusing on neuro-immune interactions; (II) determine an optimal regimen to pharmacologically inhibit S100A9 and...
The federal Project Grant award R21CA298918, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and screening of novel flupirtine analogues for the treatment of chemotherapy-induced neuropathic pain (CINP). The $179,403 grant aims to strategically synthesize potent KV7.2/7.3 activators that can effectively relieve CINP without the hepatotoxicity associated with the flupirtine parent compound. Key objectives include (1)...
This federal Project Grant award, R01CA273001, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $402,874 award will fund research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a significant adverse effect experienced by cancer patients receiving paclitaxel infusion. The research aims to determine if the acute over-excitation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $661,122 in funding to The Trustees of Columbia University in the City of New York to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to evaluate whether the accumulation of delta-2 tubulin, an irreversible tubulin modification, plays a common pathogenic role in the neuropathic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $589,106 to The Washington University in St. Louis to conduct research on the role of senescent stromal cells in chemotherapy-induced peripheral neuropathy (CIPN). The study aims to 1) elucidate the impact of senescence on axonal loss in CIPN, and 2) identify senescent cells and determine how they contribute to CIPN. The research leverages genetic mouse models and in vitro assays to...
The federal Project Grant award, R21CA297068, titled "Contribution of Cutaneous Neuro-Immune Interactions to Chemotherapy-Induced Peripheral Neuropathy," is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $426,960.00 from September 1, 2024 to November 30, 2026. The award supports research conducted by Wake Forest University Health Sciences to characterize the neuro-immune interactions in the skin of tumor-bearing mice with...